Proteolytic fragments of fibronectin containing the type III-13 and III-14 repeats induce aggrecanase activity in cartilage

Proteolytic fragments of fibronectin containing the type III-13 and III-14 repeats induce aggrecanase activity in cartilage

Detalles Bibliográficos
Autores principales:	Sofat, N, Gendron, C, Wait, R, Enghild, J, Nagase, H
Formato:	Conference item
Publicado:	2006

Ejemplares similares

THE TYPE III 8-10 REPEATS OF FIBRONECTIN INDUCE AGGRECANASE ACTIVITY VIA ALPHA5BETA1 INTEGRIN AND THE TYPE III 13-14 REPEATS ACT VIA TLR 4 RECEPTORS
por: Sofat, N, et al.
Publicado: (2009)

The type III 8-10 repeats of fibronectin induce aggrecanase activity via alpha(5)beta(1) integrin and type III 13-14 repeats act via TLR 4 receptors
por: Sofat, N, et al.
Publicado: (2009)

Tenascin-C fragments induce aggrecanase activity in cartilage
por: Sofat, N, et al.
Publicado: (2008)

Isolation of fibronectin fragments that induce aggrecan degradation in cartilage
por: Sofat, N, et al.
Publicado: (2006)

Fibronectin fragments induce aggrecan degradation in human cartilage and are increased in osteoarthritic cartilage
por: Sofat, N, et al.
Publicado: (2007)

Aggrecan breakdown in cartilage induced by proteolytic fragments of fibronectin: implications in osteoarthritis
por: Nagase, H
Publicado: (2009)

Aggrecanases in cartilage matrix breakdown
por: Nagase, H
Publicado: (2001)

Proteolytic fragments of tenascin-C promote cartilage degradation
por: Sofat, N, et al.
Publicado: (2010)

Aggrecanases and cartilage matrix degradation.
por: Nagase, H, et al.
Publicado: (2003)

Fibronectin III 13-14 domains induce joint damage via Toll-like receptor 4 activation and synergize with interleukin-1 and tumour necrosis factor.
por: Sofat, N, et al.
Publicado: (2012)

Screening for selective aggrecanase substrates to detect early proteolytic events in cartilage degradation
por: Fowkes, M, et al.
Publicado: (2018)

Collagenases and aggrecanases: understanding the role of non-catalytic domains in cartilage matrix breakdown
por: Nagase, H, et al.
Publicado: (2005)

TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors.
por: Gendron, C, et al.
Publicado: (2003)

Calcium pentosan polysulfate is a multi-functional aggrecanase inhibitor that enhances interaction with endogenous TIMP-3 in cartilage
por: Troeberg, L, et al.
Publicado: (2009)

Microvesicles shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain aggrecanase activity
por: Lo Cicero, A, et al.
Publicado: (2012)

Microvesicles shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain aggrecanase activity.
por: Lo Cicero, A, et al.
Publicado: (2012)

TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5).
por: Kashiwagi, M, et al.
Publicado: (2001)

Mapping the heparin-binding site on the 13-14F3 fragment of fibronectin.
por: Sachchidanand, et al.
Publicado: (2002)

Tenascin-C fragments are endogenous inducers of cartilage matrix degradation.
por: Sofat, N, et al.
Publicado: (2012)

Tenascin-C fragments are endogenous inducers of cartilage matrix degradation
por: Sofat, N, et al.
Publicado: (2011)

Elucidating the function of non catalytic domains of collagenases and aggrecanases.
por: Nagase, H, et al.
Publicado: (2008)

Elucidating the function of non catalytic domains of collagenases and aggrecanases
por: Nagase, H, et al.
Publicado: (2008)

Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing.
por: Kashiwagi, M, et al.
Publicado: (2004)

Aggrecanases and TIMP-3 in osteoarthritis: structure, function and in vivo challenges
por: Nagase, H
Publicado: (2009)

Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4.
por: Gendron, C, et al.
Publicado: (2007)

Fibronectin unfolding revisited: modeling cell traction-mediated unfolding of the tenth type-III repeat.
por: Elaine P S Gee, et al.
Publicado: (2008-01-01)

Fibroblast growth factor 2 inhibits induction of aggrecanase activity in human articular cartilage.
por: Sawaji, Y, et al.
Publicado: (2008)

Alterations in Fibronectin Type III Domain Containing 1 Protein Gene Are Associated with Hypertension.
por: Alan Y Deng, et al.
Publicado: (2016-01-01)

Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases.
por: Troeberg, L, et al.
Publicado: (2008)

Coculture of bovine cartilage with synovium and fibrous joint capsule increases aggrecanase and matrix metalloproteinase activity
por: Swärd, Per, et al.
Publicado: (2017)

Mannosamine inhibits aggrecanase-mediated degradation of the mechanically functional portion of proteoglycans and of the physical properties of articular cartilage
por: Patwari, Parth, 1972-
Publicado: (2014)

Effect of obesity and exercise on the expression of the novel myokines, Myonectin and Fibronectin type III domain containing 5
por: Jonathan M. Peterson, et al.
Publicado: (2014-09-01)

Fibronectin Type III Domain Containing 3B as a Potential Prognostic and Therapeutic Biomarker for Glioblastoma
por: Hyukjun Kwon, et al.
Publicado: (2023-11-01)

Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.
por: Maingot, L, et al.
Publicado: (2013)

Regulation of fibronectin and collagens type I, III and VI by TNF-α, TGF-β, IL-13, and tofacitinib
por: Frederik S. Gillesberg, et al.
Publicado: (2025-01-01)

Expression Analysis of Fibronectin Type III Domain-Containing (FNDC) Genes in Inflammatory Bowel Disease and Colorectal Cancer
por: Tilo Wuensch, et al.
Publicado: (2019-01-01)

Novel cartilage-specific splice variants of fibronectin.
por: Parker, A, et al.
Publicado: (2002)

Erratum to “Expression Analysis of Fibronectin Type III Domain-Containing (FNDC) Genes in Inflammatory Bowel Disease and Colorectal Cancer”
por: Tilo Wuensch, et al.
Publicado: (2020-01-01)

Fibronectin type III domain-containing protein 5 interacts with APP and decreases amyloid β production in Alzheimer’s disease
por: Yasuha Noda, et al.
Publicado: (2018-10-01)

Fibronectin Type III Domain-Containing 5 Attenuates Liver Fibrosis Via Inhibition of Hepatic Stellate Cell Activation
por: Bing Zhou, et al.
Publicado: (2018-07-01)